Chi-Med appoints Dr. Weiguo Su to board of directors
Hutchison China MediTech (Chi-Med) announced that Dr. Weiguo Su has been appointed as executive director and member of technical committee with effect from March 27, 2017.
Dr. Su, aged 59, has been the executive vice president and chief scientific officer of the company since 2012. Dr Su has headed all drug discovery and research since he joined the company, including master-minding the company’s scientific strategy, being a key leader of the Innovation Platform, and responsible for the discovery of each and every small molecule drug candidate in the company’s product pipeline. Prior to joining the company in 2005, Dr. Su spent 15 years with the U.S. Research and Development Department of Pfizer, with his last position as director of the Medicinal Chemistry Department.
In March 2017, Dr. Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China.